Catalog No.
Product Name
Application
Product Information
Citations
-
PROTAC Linker
Boc-C2-NH2 is an ether-based PROTAC linker that facilitates the development of proteolysis-targeting chimeras (PROTACs). This compound serves as a crucial component in the synthesis of PROTACs, enabling targeted degradation of specific proteins. Its application is integral in chemical biology and drug discovery, providing a tool for the selective modulation of protein levels in various cellular contexts. -
PROTAC Linkers
Azido-PEG5-azide is a PEG-based linker specifically designed for PROTAC synthesis, targeting the interaction of protein degradation pathways. This compound features an azide functional group that enables it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted alkyne-azide cycloaddition (SPAAC) reactions, facilitating the conjugation to alkyne-modified molecules or those containing DBCO or BCN groups. Its versatility in click chemistry applications makes it a valuable tool in the development of bifunctional PROTACs for targeted protein degradation studies. -
PROTAC Linker
trans-3-((tert-Butoxycarbonyl)amino)cyclobutanecarboxylic acid serves as a versatile PROTAC linker, facilitating the design and synthesis of proteolysis-targeting chimeras (PROTACs). This compound effectively bridges E3 ligases and target proteins, enabling targeted degradation of specific proteins within cellular systems. Its structural properties make it suitable for various research applications in targeted protein degradation and drug discovery. -
PROTAC Linker
tert-Butyl (9-aminononyl)carbamate is a PROTAC linker characterized by its alkane chain with a terminal amine and Boc-protected amino groups. This compound facilitates the synthesis of PROTACs and serves various conjugation applications. Its reactive amine group interacts with carboxylic acids, activated NHS esters, and carbonyl compounds, while the Boc group can be easily deprotected under mild acidic conditions to yield the free amine for further modifications. -
PROTAC Linker
8-Bromooctan-1-ol is a PROTAC linker used in the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the ubiquitination and degradation of target proteins by linking E3 ligases with the proteins of interest. Its primary applications include the development of targeted protein degradation strategies in chemical biology and drug discovery. -
PROTAC Linker
3-(1-(tert-Butoxycarbonyl)piperidin-4-yl)propanoic acid functions as a PROTAC linker, playing a critical role in the design and synthesis of PROTAC molecules. This compound facilitates the development of bifunctional degraders that enhance target protein degradation through the proteasome pathway. Its unique chemical structure enables efficient conjugation, making it valuable for research applications aimed at advancing targeted protein degradation techniques. -
PROTAC Linker
tert-Butyl 4-(2-hydroxyethoxy)piperidine-1-carboxylate serves as a PROTAC linker, facilitating the development of proteolysis targeting chimeras (PROTACs). This compound is critical for the construction of these bifunctional molecules, enabling targeted degradation of specific proteins within cellular pathways. Researchers utilize this linker in various applications, including drug discovery and the study of protein dynamics. -
PROTAC Linker
tert-Butyl (7-aminoheptyl)carbamate serves as a versatile PROTAC linker, facilitating the design and synthesis of targeted protein degradation compounds. This linker is instrumental in creating compounds like CPD-10, enabling research into targeted therapies and proteomics. Its structure allows for efficient conjugation with various ligands, supporting advancements in drug discovery and development in the field of molecular biology. -
PROTAC Linker
tert-Butyl 4-(3-hydroxypropyl)tetrahydropyridine-1(2H)-carboxylate is a versatile PROTAC linker designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the selective degradation of proteins by linking ligands that recruit E3 ligases to target proteins, enhancing the efficacy of targeted protein degradation strategies. It is essential for researchers focused on developing innovative therapeutic approaches in the field of targeted protein modulation. -
PROTAC Linker
(3-Bromopropoxy)(tert-butyl)dimethylsilane serves as a key PROTAC linker utilized in the development of proteolysis-targeting chimeras (PROTACs). This compound facilitates the connection between target proteins and E3 ligases, promoting the targeted degradation of specific proteins within cellular environments. Its application in PROTAC synthesis supports advancements in targeted protein degradation research and therapeutic strategies. -
PROTAC Link
mPEG45-diol is a polyether-based PEG derivative designed as a linker for PROTAC (Proteolysis Targeting Chimera) synthesis. Its functional properties facilitate the conjugation of small molecules to E3 ligases, enabling targeted degradation of specific protein targets within cellular systems. This compound is vital for optimizing the design and efficacy of PROTAC molecules in cellular and molecular biology research applications. -
PROTAC Linker
2-(tert-Butoxycarbonyl)-2-azaspiro[3.3]heptane-6-carboxylic acid serves as a crucial PROTAC linker in the development of proteolysis targeting chimeras. This compound facilitates the connection between target proteins and E3 ligases, enabling targeted degradation pathways. It is particularly valuable in research focused on protein regulation and therapeutic development for various diseases. -
PROTAC Linker
6-Heptyn-1-ol is a PROTAC linker characterized by its alkyne functional group, facilitating the construction of Proteolysis Targeting Chimeras (PROTACs). It serves as a vital component for the conjugation of different moieties, enhancing the targeted degradation of specific proteins of interest. This compound is instrumental in research applications focused on elucidating protein function and developing novel therapeutic strategies. -
PROTAC Linker
Boc-(7-Azaspiro[3.5]nonane)-NH2 is a versatile PROTAC linker designed for the synthesis of proteolysis-targeting chimeras (PROTACs). This compound facilitates the effective conjugation of target proteins and E3 ligases, enabling enhanced degradation of specific proteins within cells. Its unique structural properties make it suitable for a variety of research applications in targeted protein degradation, offering potential for therapeutic advancements in various disease models. -
PROTAC Linker
2-(4-(((tert-butoxycarbonyl)amino)methyl)phenyl)acetic acid serves as a PROTAC linker essential for the synthesis of PROTAC molecules. This compound plays a critical role in the development of targeted protein degradation strategies, facilitating the selective elimination of specific proteins within cellular environments. It is valuable for research applications in drug discovery and proteomics, enabling innovative approaches to modulating protein levels in various biological systems. -
PROTAC Linker
8-Bromooctanoic acid functions as a PROTAC linker, enabling targeted protein degradation through the formation of heterobifunctional molecules. This compound plays a crucial role in the synthesis of PROTAC CYP1B1 degrader-2, facilitating the selective degradation of the CYP1B1 protein for various research applications. Its unique chemical structure supports the development of innovative therapeutic strategies in the field of cancer research and beyond. -
PROTAC Linkers
Mal-PEG12-NHS ester is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs (proteolysis-targeting chimeras). This compound features an NHS ester group, facilitating the conjugation of target proteins or ligands. Mal-PEG12-NHS ester serves as an effective tool in chemical biology research, enabling the development of novel therapeutic strategies through targeted protein degradation. -
PROTAC Linker
Bromo-PEG5-Boc is a polyethylene glycol (PEG)-based linker designed for use in the synthesis of PROTACs (proteolysis targeting chimeras). This compound features a bromo group that facilitates the recruitment of E3 ligases, enabling targeted degradation of specific proteins within the cell. Bromo-PEG5-Boc is essential in developing innovative therapeutic strategies that leverage the ubiquitin-proteasome system for the selective removal of pathogenic proteins. Its application extends to various fields of research, including cancer biology and drug discovery. -
PROTAC Linker
1,7-Bis-Boc-1,4,7-triazaheptane is a versatile alkyl/ether-based linker specifically designed for the synthesis of PROTACs (Proteolysis Targeting Chimeras). Its structure facilitates the creation of bifunctional molecules that engage target proteins for degradation via the ubiquitin-proteasome system. This compound is essential for researchers exploring targeted protein regulation and novel therapeutic strategies in the field of drug discovery. -
PROTAC Linkers
Biotin-PEG3-acid is a biotin-labeled linker featuring a polyethylene glycol (PEG) moiety, specifically designed for use in the synthesis of PROTACs (PROteolysis TArgeting Chimeras). This compound facilitates targeted degradation of proteins by linking E3 ligases to the proteins of interest, promoting ubiquitination and subsequent proteasomal degradation. With its application in drug discovery and development, Biotin-PEG3-acid supports the study of protein function and regulation in various biological contexts. -
PROTAC linker
Biotin-PEG4-acid is a PEG-based linker designed for use in proteolysis-targeting chimeras (PROTACs). This compound facilitates the efficient synthesis of PROTACs by providing a biotin moiety that enhances target protein degradation. Its application is critical in studies related to targeted protein degradation and drug discovery, enabling researchers to explore novel therapeutic strategies. -
PROTAC Linkers
Azido-PEG2-C6-Cl is a PEG-based linker specifically designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). This compound features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing partners. Additionally, it readily engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with dibenzocyclooctyne (DBCO) or bicyclononyne (BCN)-bearing molecules. These properties make Azido-PEG2-C6-Cl a versatile tool for advancing targeted protein degradation research. -
PROTAC Linker
Azido-PEG3-C6-Cl is a PEG-based linker designed for use in the synthesis of proteolysis targeting chimeras (PROTACs). This compound features an azide group that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) with dibenzocyclooctyne (DBCO) or bicyclononyne (BCN) groups. It serves as a versatile tool in chemical biology, enabling the creation of targeted protein degraders for research applications in drug discovery and therapeutic intervention. -
NR4A1 PROTAC Degrader
NR-V04 is a selective degrader targeting NR4A1 via a PROTAC mechanism. It facilitates the formation of a ternary complex with NR4A1 and the VHL E3 ligase, promoting proteasome-dependent degradation of NR4A1. Through its action, NR-V04 has been shown to enhance the infiltration of tumor-associated B cells and effector memory CD8+ T cells while decreasing monocytic myeloid-derived suppressor cells within tumor microenvironments. This compound is valuable for research related to melanoma and colon cancer. -
CRBN Degrader
ZXH-4-130 TFA is a potent and selective degrader of Cereblon (CRBN), functioning as a CRBN-VHL heterobifunctional protein degrader (PROTAC). This compound exhibits significant biological activity, inducing approximately 80% CRBN degradation at a concentration of 10 nM in MM1.S cells. ZXH-4-130 TFA is a valuable tool for investigating CRBN-mediated pathways and protein degradation mechanisms in various research applications. -
LDH-targeted PROTAC
MS6105 is a selective LDH-targeted PROTAC that induces the degradation of LDHA and LDHB through the ubiquitin-proteasome system. This compound exhibits notable anticancer activity, making it a valuable tool for cancer research. Additionally, MS6105 features an alkyne group, facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, enabling diverse applications in chemical biology and drug discovery. -
PD-L1-PROTAC Degrader
PROTAC PD-L1 degrader-1 is a CRBN-based protein degrader targeting PD-L1, facilitating the selective degradation of the PD-L1 protein. This compound demonstrates potent PD-L1 degradation in 4T1 cells, with a DC50 value of 0.609 μM. It serves as a valuable tool for investigating therapeutic approaches in breast cancer research. -
PROTAC ERα Degrader
ERD-3111 is an orally active PROTAC degrader targeting estrogen receptor alpha (ERα) with a reported DC50 of 0.5 nM. This compound effectively inhibits tumor growth in both wild-type MCF-7 xenograft models and in models harboring clinically relevant ESR1 mutations. ERD-3111 is a valuable tool for research focused on estrogen receptor-positive breast cancer, facilitating investigations into targeted degradation pathways and therapeutic strategies. -
PROTAC ER Degrader
PROTAC ER Degrader-4 is a von Hippel-Lindau-based PROTAC that targets the estrogen receptor (ER). It demonstrates high potency, binding to ER with an IC50 of 0.8 nM, and effectively induces ER degradation in MCF-7 cells with an IC50 of 0.3 nM. This compound is valuable for research applications focused on hormone receptor signaling and targeted protein degradation. -
VHL-type PROTAC degrader
PROTAC VHL-type degrader-1 is a VHL-type PROTAC degrader that facilitates the targeted degradation of the ATM protein. This compound enhances the efficacy of the ATR inhibitor AZD6738 through a synergistic mechanism, making it a valuable tool for investigating the interplay between ATM and ATR signaling pathways. It is applicable in research focusing on cancer therapeutics and cellular response to DNA damage. -
PROTACs
AZ'6421 is a Protcolysis Targeting Chimera (PROTAC) designed to selectively degrade estrogen receptor alpha. It exhibits potent anti-tumor activity, effectively inhibiting uncontrolled cellular proliferation associated with malignancies. AZ'6421 is primarily utilized in cancer research, particularly for investigating breast cancer and its therapeutic strategies. -
PCLAF Inhibitor
AD4 is a proteolytic targeting chimera (PROTAC) designed to inhibit PCLAF. This compound effectively degrades PCLAF in RS4;11 cells with an IC50 of 0.6 nM, leading to the activation of the p21/Rb pathway and demonstrating anti-tumor effects. In vivo studies have shown that AD4 prolongs survival in RS4;11-transplanted NOD/SCID mice, highlighting its potential for cancer research applications. -
SMARCA2 PROTAC degrader
YD54 is a PROTAC designed to induce degradation of the SMARCA2 protein, exhibiting a DC50 of 3.5 nM. This compound utilizes a targeted approach to promote the ubiquitination and proteasomal degradation of SMARCA2, making it a valuable tool for studying SMARCA2-dependent biological processes. YD54 is suitable for applications in cancer research and cellular signaling investigations, where modulation of SWI/SNF complex activity is critical. -
PARK7 Degrader
JYQ-194 is a proteolysis-targeting chimera (PROTAC) designed to degrade human PARK7, a protein implicated in Parkinson's disease. This reagent serves as a valuable tool for investigating the underlying mechanisms of neurodegeneration and cancer biology. Its ability to selectively target and degrade PARK7 highlights its potential utility in therapeutic applications and biological research related to Parkinson's disease and other neurodegenerative conditions. -
PROTAC Axl Degrader
PROTAC Axl Degrader 2 is a selective proteolysis-targeting chimera (PROTAC) that degrades Axl with an IC50 of 1.61 μM. This compound exhibits significant anti-proliferation and anti-migration activities in vitro. Additionally, PROTAC Axl Degrader 2 induces mehuosis, making it a valuable tool for studying Axl’s role in cancer progression and therapeutic resistance. Potential research applications include investigations into targeted degradation as a therapeutic strategy in oncology. -
STAT3 PROTAC Degrader
PROTAC STAT3 degrader-3 (S3D1) targets the STAT3 protein through a PROTAC-mediated degradation mechanism. This compound exhibits potent anticancer activity by facilitating the ubiquitination and subsequent proteasomal degradation of STAT3, a key oncogenic transcription factor. It is primarily applied in research focused on cancer biology, particularly in studies investigating the therapeutic potential of targeting the STAT3 signaling pathway. -
Threonine Tyrosine Kinase PROTAC Degrader
PROTAC TTK degrader-1 is a selective threonine tyrosine kinase (TTK) PROTAC degrader designed to induce target degradation. It demonstrates potent biological activity, with DC50 values of 1.7 nM and 5.8 nM in COLO-205 and HCT-116 cell lines, respectively. This compound exhibits significant anticancer efficacy in xenograft mouse models utilizing COLO-205 human colorectal cancer cells, making it a valuable tool for research in cancer therapeutics and targeted protein degradation. -
DDR1 PROTAC Degrader
PROTAC DDR1 degrader-1 is a PROTAC-based degrader designed to selectively target the discoidin domain receptor 1 (DDR1) for proteasomal degradation. This compound utilizes a specific DDR1 inhibitor linked to an E3 ligase ligand, facilitating targeted protein degradation. It exhibits potential applications in elucidating DDR1's role in various cellular processes and disease states, providing valuable insights for therapeutic research. -
CRBN-type PROTAC
WH-10417-099 is a CRBN-type PROTAC designed to induce the degradation of over 125 unique kinases through the ubiquitin biotinylation (E-STUB) mechanism. Its structure comprises a PI3Kγ ligand, a Thalidomide 4-fluoride E3 ubiquitin ligase ligand, and an Amino-PEG5-C2-acid linker. This compound is valuable for research into targeted protein degradation and multi-kinase signaling pathways, with potential applications in cancer and other diseases characterized by dysregulated kinase activity. -
PROTAC erf3a Degrader
PROTAC erf3a Degrader-1 is a potent oral degrader designed to target the erf3a protein. This compound exhibits significant anti-proliferative activity against various cancer cell lines, including 22Rv1, making it a valuable tool in cancer research. PROTAC erf3a Degrader-1 is particularly relevant for studies focused on prostate, ovarian, liver, cervical, and breast cancers, as well as leukemia, facilitating the investigation of targeted protein degradation in these malignancies. -
USP7 PROTAC Degrader
CST967 is a USP7 PROTAC degrader that facilitates targeted degradation of the USP7 protein through the ubiquitin-proteasome pathway. By modulating PROTAC concentration, researchers can significantly enhance the degradation rate of USP7, a key regulator in various cellular processes. This compound is valuable in cancer research for investigating the functional consequences of USP7 inhibition and exploring novel therapeutic strategies. -
SMARCA2 Degrader
PROTAC SMARCA2 degrader-8 is a selective degrader targeting the SMARCA2 protein, exhibiting a DC50 of 28 nM in A375 cells. This compound facilitates the ubiquitination and subsequent proteasomal degradation of SMARCA2, thereby effectively reducing its cellular levels. It is particularly useful for studies investigating the role of SMARCA2 in various cancer types and for elucidating its mechanisms of action in cellular processes. -
CRBN Degrader
ZXH-4-130 is a selective degrader of cereblon (CRBN) utilizing the CRBN-VHL mechanism. This compound effectively facilitates the degradation of target proteins through the ubiquitin-proteasome pathway, making it a valuable tool in studying protein homeostasis and degradation processes. Its applications extend to research in targeted protein degradation and the exploration of CRBN's role in various biological contexts. -
BRD4 PROTAC
MS83 is a novel PROTAC that employs a KEAP1 ligand to target and degrade BRD4, along with its homologs BRD3 and BRD2. By harnessing the ubiquitin-proteasome system, MS83 facilitates targeted protein degradation, providing a powerful tool for dissecting the functional roles of BRD4 in cellular processes. This compound is particularly relevant for research on cancer and epigenetic regulation, offering insights into therapeutic strategies that leverage targeted protein degradation. -
BRD9 Degrader PROTAC
PROTAC BRD9 Degrader-5 is a proteolysis-targeting chimera (PROTAC) that facilitates the targeted degradation of the bromodomain-containing protein BRD9. This compound employs the cellular ubiquitin-proteasome pathway to promote the selective elimination of BRD9, leading to the modulation of biological pathways associated with cancer and other diseases. It serves as a valuable tool for researchers investigating the role of BRD9 in various cellular processes and therapeutic interventions. -
PROTAC Pirin Degrader
CCT367766 is a third-generation heterobifunctional PROTAC designed to target and degrade the pirin protein through the CRBN-DDB1 complex. This compound effectively reduces pirin expression at low concentrations, demonstrating an IC50 of 490 nM. It exhibits high binding affinities for recombinant pirin and CRBN, with Kd values of 55 nM and 120 nM, respectively. CCT367766 serves as a valuable chemical tool for probing the biological functions of pirin and advancing research in proteolysis-targeting chimeras. -
Photocaged-PROTAC
phoBET1 is a photocaged-PROTAC targeting BRD4 for selective degradation. This compound harnesses light-activated control to induce the degradation of BRD4 protein, resulting in significant suppression of tumor growth. Its unique photocaging mechanism allows for spatial and temporal regulation of protein activity, making it a valuable tool for studying the role of BRD4 in cancer biology and therapeutic applications. -
Threonine Tyrosine Kinase PROTAC Degrader
PROTAC TTK degrader-2 is a potent degrader that targets threonine tyrosine kinase (TTK), demonstrating DC50 values of 3.1 nM in COLO-205 cells and 12.4 nM in HCT-116 cells. This compound effectively induces target protein degradation and exhibits anticancer activity in a xenograft mouse model of human colorectal cancer derived from COLO-205 cells. It serves as a valuable tool for investigating TTK's role in cancer biology and may aid in the development of novel therapeutic strategies. -
SIAIS630121 Negative Control
SIAIS630121-NC is a negative control compound designed for use alongside the NAMPT (nicotinamide phosphoribosyltransferase) PROTAC degrader SIAIS630121. This compound demonstrates no degradation activity on NAMPT, serving as a baseline reference for experimental validation. SIAIS630121-NC is essential for researchers studying the effects of NAMPT degradation and the role of PROTAC technology in targeted protein modulation. -
SMARCA2 Degrader degrader
SMARCA2 degrader-20 is a potent PROTAC that targets the SMARCA2 protein for degradation, exhibiting a DC50 of less than 100 nM in A549 cells. This degrader is valuable for studying the functional consequences of SMARCA2 depletion in cancer biology and epigenetic regulation. Its high efficacy facilitates research into targeted protein degradation strategies and their therapeutic potential in oncology.
